A new Institute of Medicine (IOM) report addresses growing concerns in the global community surrounding the public safety matters of fake and substandard drugs.
Formulary Watch
Latest News
All News
Advertisement
In the last 10 years, many patients have developed unexpected toxicities from prescription drugs that have been on the market for 5 to 10 years, according to the Consumer Health Information Corp.
A single corticosteroid injection to treat unilateral lateral epicondylalgia-tennis elbow-is linked to poorer outcomes after 1 year, according to a study published February 6 in JAMA.
The National Breast Cancer Coalition recently awarded a nearly $200,000 seed grant to two researchers who will study the viral connection to breast cancer. The research will assess the infectious agent in breast tumors compared to normal breast tissue, which could lead to a preventive vaccine.
FDA has granted priority review to oncology compound radium-223 dichloride (radium-223, Bayer HealthCare) for the treatment of castration-resistant prostate cancer (CRPC) patients with bone metastases.
Vitamin D supplementation does not slow progression of knee osteoarthritis or reduce pain associated with the condition, according to a study published recently in the Journal of the American Medical Association.
Shared decision-making with patient and health-coach involvement saves on overall costs of care. Specifically, the technique reduces hospitalizations and surgeries, according to a study published in Health Affairs (February 2013).
A leading epidemiologist recently suggested alternative treatments for the fungal meningitis outbreak late last year. To date, 46 deaths have been linked to contaminated steroids from compounding pharmacies.
FDA has approved pomalidomide (Pomalyst, Celgene) to treat patients who have received at least 2 prior therapies including lenalidomide and bortezomib and have demonstrated disease progression on or within 60 days of completion of the last therapy.
Physicians who attended a medical school with an active gift restriction policy were subsequently less like to prescribe newly marketed psychotropic medications over older, cheaper alternatives, according to a study published in the January 2013 issue of BMJ.
Advertisement
Calcium from diet sources was not related to death from cardiovascular disease in women, but may increase the risk in men, according to a study published recently in JAMA Internal Medicine.
Despite availability of many therapies indicated for bowel disorders, there is still an unmet need and heterogeneity among these patients, necessitating availability of a wide variety of therapeutics. Awareness of potential new products, their key benefits, and where they may fit into the treatment paradigm will be important when making decisions impacting patients and physicians, according to new analysis.
FDA issued a proposal designed to assist companies developing new treatments for patients in the early stages of Alzheimer’s disease, before the onset of overt dementia.
FDA has alerted healthcare professionals that a counterfeit version of the cancer drug Avastin was distributed in the United States.
Because Tamiflu has been in short supply recently, pharmacists and other healthcare providers are being warned about confusion over emergency compounding of the drug.
The American Academy of Pediatrics (AAP) has published a policy statement to provide pediatricians with recommendations for assessing and treating Clostridium difficile infections (CDI) in children.
FDA’s approval of the first generic version of the cancer drug Doxil (doxorubicin hydrochloride liposome injection) could help alleviate shortages.
A majority of pharmacists and other healthcare practitioners believe that pharmacists need to disclose the source of high-risk compounded sterile preparations (CSPs) to prescribers, according to a recent survey.
Canagliflozin is a sodium glucose co-transporter inhibitor under review for FDA approval for the treatment of type 2 diabetes mellitus.
Patients who take a combination of diuretics and either angiotensin converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs) and add NSAIDs, have an increased risk of acute kidney injury, according to a study online in BMJ.
Polypharmacy screening has the significant potential to improve medication safety.
FDA and the Federal Trade Commission (FTC) issued a warning letter to Flu and Cold Defense LLC (Boca Raton, Fla.) for making misleading, unproven claims about its GermBullet inhaler, and said the company has been marketing an untested inhaled formula as a flu remedy in violation of drug safety regulations.
FDA has approved mipomersen sodium (Kynamro, Genzyme and Isis Pharmaceuticals) once-a-week injection as an addition to lipid-lowering medications and diet to treat patients with a rare type of high cholesterol called homozygous familial hypercholesterolemia (HoFH). The addition of Kynamro helps to reduce low-density lipoprotein-cholesterol (LDL-C), apolipoprotein B, total cholesterol, and non-high density lipoprotein-cholesterol (non HDL-C).
The public is generally satisfied with cancer research progress over the past 20 years. However, they believe it takes too long for new cancer drugs to reach patients and that their countries invest too little in fighting cancer, according a global survey.
Recent FDA action (through January 2013) related to, IPX066, Afatinib, Enobosam, GTx-024, Elafin, Ezatiostat HCL, Tranexamic acid tablets, Lamotrigine extended-release tablets
New molecular entity: A benzodiazepine indicated for adjunctive treatment of seizures associated with Lennox-Gastaut syndrome (LGS) in patients age 2 years or older.
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
Global MS analysis links disability burden to rising economic strain
2
HS patients on biosimilar adalimumab lose response faster than those on the original drug
3
New drug class shows promise for geographic atrophy
4
CMS negotiates a 70% discount for Ozempic and Wegovy
5
